3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
7
Unknown
6
Completed
5
Withdrawn
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Conditions
Ovarian Neoplasms
109
Uterine Cervical Neoplasms
57
Endometrial Neoplasms
38
Fallopian Tube Neoplasms
34
Carcinoma, Ovarian Epithelial
27
Breast Neoplasms
25
Neoplasms
15
Carcinoma, Non-Small-Cell Lung
13
Pancreatic Neoplasms
12
Uterine Cervical Dysplasia
11
Recurrence
11
Stomach Neoplasms
10
Neoplasm Metastasis
10
Lung Neoplasms
9
Colorectal Neoplasms
9
Uterine Neoplasms
8
Triple Negative Breast Neoplasms
8
Sarcoma
8
Urinary Bladder Neoplasms
7
Melanoma
6
Esophageal Neoplasms
6
Vulvar Neoplasms
5
Vaginal Neoplasms
5
Testicular Neoplasms
5
Lymphoma, Non-Hodgkin
5
Small Cell Lung Carcinoma
4
Sezary Syndrome
4
Rectal Neoplasms
4
Prostatic Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Interventions
Nivolumab
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Lymphatic Metastasis
×
Gynecologic
×
Clear all
NCT05504642
2023-04-18
CERAD-IMMUNE
Universitätsklinikum Köln
Phase 2
Withdrawn